Skip to search formSkip to main contentSkip to account menu

saracatinib

Known as: 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, N-(5-Chloro-1,3-Benzodioxol-4-Yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-((Oxan-4-yl)Oxy)Quinazolin-4-Amine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine 
An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of… 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (1)

AZD 0530

Broader (4)

Antineoplastic AgentsBenzodioxolesEnzyme InhibitorsQuinazolines
Cell Migration Inhibition functionInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
This is a repository copy of A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
BACKGROUND: Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth… 
2017
2017
Impaired activity of adherens junctions contributes to endothelial dilator dysfunction in ageing rat arteries
Ageing‐induced endothelial dysfunction contributes to organ dysfunction and progression of cardiovascular disease. VE‐cadherin… 
2016
2016
Saracatinib as a metastasis inhibitor in metastatic castration‐resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study
Fyn is a kinase that is upregulated in a subset of metastatic castration‐resistant prostate cancer. Saracatinib potently inhibits… 
2014
2014
The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer
The anti-ErbB2 antibody trastuzumab has shown significant clinical benefits in ErbB2-overexpressing breast and gastric cancer… 
2014
2014
Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors
Diffuse‐type gastric carcinomas (DGC) exhibit more aggressive progression and poorer prognosis than intestinal‐type and other… 
Highly Cited
2012
Highly Cited
2012
MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma
Introduction: MicroRNAs are small, noncoding RNAs that suppress gene expression by binding to the 3’ untranslated region (UTR… 
Review
2011
Review
2011
The integrin signalling adaptor p130CAS is also a key player in prostate cancer
In a recent Review article (Integrin signalling adaptors: not only figurants in the cancer story. Nature Rev. Cancer 10, 858–870… 
Highly Cited
2011
Highly Cited
2011
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
Antiestrogen therapies arrest susceptible estrogen receptor (ER)-positive breast cancers by increasing p27. Since Src… 
2010
2010
Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
BACKGROUND Src, a non-receptor tyrosine kinase frequently overexpressed and highly activated in malignancies, has been associated… 
2010
2010
A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic pancreatic cancer.
e14515 Background: Src family tyrosine kinases are overexpressed in pancreatic cancers, and the oral Src inhibitor saracatinib… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)